Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma
New data show that epcoritamab is an effective off-the-shelf therapy for both CAR T-exposed and CAR T-naive patients with R/R LBCL who had already received prior lines of therapy.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen